ARGX vs DNTH: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ARGX and DNTH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ARGX and DNTH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

argenx SE is a Netherlands-based, globally operating immunology company that trades in the US as a Nasdaq ADR. Its lead product, Vyvgart and the subcutaneous Vyvgart Hytrulo (efgartigimod), is an FcRn blocker that lowers pathogenic IgG antibodies. It is approved for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), plus primary immune thrombocytopenia in Japan, and reached roughly 19,000 patients on treatment by the end of 2025.

Full ARGX guide

Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing claseprubart (DNTH103), an antibody that selectively blocks the active form of the C1s enzyme in the complement system's classical pathway while leaving the alternative and lectin pathways intact to preserve immune defense. Using half-life-extension (YTE) technology, the drug is designed for infrequent, low-volume subcutaneous self-injection (as seldom as once every four weeks), which the company positions as a convenience advantage over infused or more frequently dosed rivals. The lead programs target rare autoimmune and neuromuscular diseases: chronic inflammatory demyelinating polyneuropathy (CIDP), generalized myasthenia gravis (gMG), and multifocal motor neuropathy (MMN).

Full DNTH guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ARGX drivers: Vyvgart franchise momentum; Label and indication expansion.
• DNTH drivers: Phase 3 CIDP readout (CAPTIVATE); Generalized myasthenia gravis expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. For DNTH, as a pre-revenue, essentially single-asset company, DNTH faces concentrated clinical risk: a failed or ambiguous Phase 3 readout in CIDP or gMG could sharply reduce the value of the entire pipeline.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ARGX if you believe its drivers more; DNTH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ARGX and DNTH guides.

ARGX. At ~31x trailing and ~23x forward earnings, argenx is valued as a profitable growth company rather than a speculative biotech, with consensus expecting revenue of ~$6.3 billion in 2026 and ~$7.76 billion in 2027. The Sjogren's failure trimmed some pipeline value from the price, and the mean analyst target of ~$1,153 across 23 analysts sits well above the $817.80 close. Third-quarter results on October 22, 2026 (consensus revenue ~$1.63 billion) are the next check on Vyvgart growth.

DNTH. Standard valuation multiples do not apply because Dianthus has no product revenue and runs at a loss funding clinical trials. The market cap has come down to about $3.9 billion from the roughly $4.8 billion of mid-2026 after a 26% one-month drop, though it is still about 80% higher than at the start of the year. The analyst average target near $141 is about double the October 16 close, so the gap between sell-side and market expectations for the CAPTIVATE readout is wide.

Headline figures (approximate, October 2026): ARGX shows revenue (ttm) ~$5.32B; Q2 2026 ~$1.54B, up ~59% year over year, q2 2026 eps $7.32 vs $6.19 consensus; profit ~$472M, net income (ttm) ~$1.72B; net margin ~32%, p/e ~31x trailing, ~23x forward; DNTH shows revenue (ttm) ~$1.9M (license and collaboration income; no product sales), net loss (ttm) ~$192M; Q2 2026 loss ~$50M, EPS -$0.90 vs -$0.91 consensus, market cap ~$3.9B at a $71.38 close on Oct 16, 2026, cash ~$887M at June 30, 2026 per Yahoo Finance; company cites ~$1.1-1.2B and runway into 2030.

ARGX and DNTH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ARGX and DNTH exposure against your real portfolio. It is not an investment adviser.